StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) company profile

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

About Veracyte

Services-Medical Laboratories, SIC 8071

Veracyte is a molecular diagnostics company that develops and performs clinical genomic tests to assist in diagnosing and treating various forms of cancer. Its primary commercial offerings include Decipher tests for prostate and bladder cancers, the Afirma classifier for thyroid nodules, and the Prosigna assay for breast cancer. The business operates through laboratory developed tests analyzed in centralized facilities as well as distributed in vitro diagnostic test kits. Its customers include physicians, endocrinologists, oncologists, hospitals, independent laboratories, and biopharmaceutical partners.

In the United States, the company operates three clinical reference laboratories located in South San Francisco, California; San Diego, California; and Austin, Texas. Outside the United States, it distributes test kits across Europe, the Middle East, Asia Pacific, Latin America, and Canada. Its diagnostic products receive reimbursement across numerous countries, including Germany, France, Spain, Italy, Canada, and Israel. The provided text notes these operating facilities but does not identify a corporate headquarters.

Summary of the business section of Veracyte's latest annual report, written by StockData.

Company profile

Company

Legal name
Veracyte, Inc.
Headquarters
South San Francisco, CA
Address
6000 Shoreline Court, Suite 300 94080
Phone
(650) 243-6300
Employees
755, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
VCYT
Exchange
Nasdaq
IPO date
Oct 30, 2013
Shares outstanding
80M, Jul 27, 2026
Public float
$1.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1384101
CUSIP
92337F107
ISIN
US92337F1075
FIGI
BBG001J2M542
Share class FIGI
BBG001TSQWW0
LEI
529900ESWZRHXOW27Z37
EIN
20-5455398

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Marc StapleyChief Executive Officer, Director432,073
Jonathan WygantVP, Chief Accounting Officer41,920
John LeiteGlobal Chief Commercial Off124,329
Phillip G. FebboChief Scientific & Med Officer133,048
Rebecca ChambersChief Financial Officer167,200
Annie McGuireEVP, General Counsel132,260
Kevin Richard HaasChief Dev and Tech Officer44,221
Jens HolsteinDirector27,471
Karin EasthamDirector11,488
Muna BhanjiDirector40,854
Robert S. EpsteinDirector57,718
Evan/ Fa JonesDirector34,634
David Brent ShaferDirector31,100
Eliav BarrDirector56,461
Thomas F. MillerDirector31,100

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.42M$9.61M$2.84M$86$125
FY2024$6.82M$14.89M$3.15M$81$93
FY2023$7.18M$9.56M$2.74M$56$94
FY2022$4.94M$1.62M$3.73M$48$90
FY2021
Anderson
$4.52M$2.88M$2.24M$84$100
FY2021
Stapley
$5.74M$5.70M$2.24M$84$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Marc Stapley
Chief Executive Officer
$700.00K$5.89M$826.00K$5.00K$7.42M+9%
Rebecca Chambers
Chief Financial Officer
$550.00K$1.96M$356.95K$5.00K$2.88M-21%
Phillip Febbo
Chief Scientific Officer and Chief Medical Officer
$561.00K$1.57M$364.09K$5.00K$2.50M-10%
John Leite
Global Chief Commercial Officer
$510.30K$2.36M$331.19K$5.00K$3.20M+4%
Annie McGuire
General Counsel and Head of Market Access
$500.00K$1.96M$324.50K$5.00K$2.79M-10%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 30, 2013
Securities offered
5,000,000
Exchange
Nasdaq
First trading day
Oct 30, 2013
First-day close
$13.25
Lock-up ends (est.)
Apr 28, 2014

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 755 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?